NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

Defiant kingpin Merck has better plans

re OVERZEALOTS
DStock/Slave1 Evanston’s ETC AL

Pie in the SKY & lacking the EXTRA mile until validated by MAESTRO & Markets

Merck in talks to buy biotech Revolution in up to $32 billion deal, FT reports

Jan 8 (Reuters) - Merck (MRK.N), opens new tab is in talks to buy cancer drug developer Revolution Medicines (RVMD.O), opens new tab in a $28 billion to $32 billion deal, the Financial Times reported on Thursday, citing a person familiar with the matter.
Revolution shares jumped nearly 16% in extended trading following the report.

Merck has been pursuing an acquisition of Revolution Medicines, however, a deal has not been finalised, the report said, citing people familiar with the matter, adding a tie-up would be at least several weeks away.

Other large pharmaceutical groups were still circling the biotech and another suitor might yet prevail, the FT report said, adding a transaction is not a foregone conclusion.

A potential buyout of Revolution by Merck would mark the biggest deal in the pharmaceutical sector in nearly three years since Pfizer's $43 billion takeover of cancer biotech Seagen.

Revolution Medicines and Merck did not immediately respond to Reuters' requests for comment.

Merck, which is set to lose patents for its blockbuster cancer treatment Keytruda later this decade, has nearly tripled its late-stage pipeline since 2021 through in-house development and big deals such as the $11.5 billion purchase of Acceleron for pulmonary arterial hypertension drug Winrevair.

A deal with Revolution could give Merck access to its experimental drug daraxonrasib, which is in late-stage trials and has won a fast-track review voucher from the U.S. Food and Drug Administration.

The drug is designed to target multiple mutations in the RAS genes, which are common drivers of major cancers, including certain pancreatic, lung and colorectal cancers.
Mizuho analysts estimate more than $10 billion in potential risk-adjusted sales globally from Revolution's portfolio of RAS inhibitors by 2035.
The FT article came a day after the Wall Street Journal reported that AbbVie (ABBV.N), opens new tab was in advanced talks to buy Revolution, a claim the drugmaker later denied.

https://www.reuters.com/business/healthcare-pharmaceuticals/merck-talks-buy-biotech-revolution-medicines-ft-reports-2026-01-08/

Daraxonrasib
Pharmaceutical compound
Daraxonrasib (RMC-6236) is an investigational new drugbeing evaluated by Revolution Medicines to treat advanced solid tumors with RAS mutations, especially metastatic pancreatic ductal adenocarcinoma (PDAC) containing KRAS G12X mutations.[1] It has received a breakthrough therapy designation from the U.S. Food and Drug Administration.[2]
Quick facts Clinical data, Other names ...
Daraxonrasib is an orally active, multi-selective RAS inhibitor that uses a novel tri-complex mechanism to target the active, GTP-bound form of RAS proteins, including mutant and wild-type types. Unlike conventional RAS inhibitors, it first binds to the chaperone-like protein cyclophilin A to form a complex, which then attaches to active RAS. This interaction blocks downstream effector binding and inhibits oncogenic signaling.[3]
As of 2025, Daraxonrasib clinical trial is in phase 3 to assess efficacy compared to current standard-of-care chemotherapy.

BTW
Everyone dismissed TNXPs a NO BRAINER Fall 2024:
TNXP is much farther ahead than NWBO in many respects

Too many think they know buthve demonstrated otherwise.

Give them enough rope and they will hang themselves


DIFFERENT STROKES for DIFFERENT FOLKS